Project Grant R56HL169244
Award Date
9/1/23
Completion Date
8/31/24
Dollars Obligated
$436K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Albert Einstein College of Medicine. The grant, awarded on July 9, 2025, will fund research to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis in zebrafish and human induced pluripotent stem cells. The project aims to provide mechanistic insights into how these co-occurring mutations contribute to the...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $146,922 to the Albert Einstein College of Medicine to investigate the mechanisms driving hematopoietic stem and progenitor cell (HSPC) dysfunction associated with the inherited form of myelodysplastic syndrome (MDS). The research aims to decipher how environmental factors synergize with the DDX41 gene mutation to promote HSPC dysfunction, including the potential...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $165,080 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Dana-Farber Cancer Institute (DFCI) in Boston, MA. The grant will fund a 5-year research project led by Dr. Lachelle D. Weeks to define the relationship between clonal hematopoiesis (CH) and inflammatory disease outcomes. The project aims to: 1) Determine the association between CH and rheumatologic diseases, 2) Identify CH genotypes...
This Project Grant award of $240,750.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research), supports the development of advanced mouse models to study the cellular and molecular mechanisms underlying myelodysplastic syndromes (MDS) caused by mutations in the DDX41 gene. The project aims to generate mouse models that accurately reflect the natural progression of DDX41-mutated MDS, including...
The National Heart, Lung, and Blood Institute awarded a $1,999,247 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research to investigate the factors underlying success and failure of allogeneic virus-specific T-cell therapy in treating viral infections in patients who have undergone hematopoietic stem cell transplantation. The research aims to improve understanding of both patient-specific and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $773,257 to St. Jude Children's Research Hospital Inc. to investigate the mechanisms of lysosome segregation and cell fate regulation in dividing hematopoietic stem cells (HSCs). The research aims to identify factors regulating lysosome segregation during HSC division and how this process influences HSC self-renewal and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $680,321 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research on how the protein DLK1 regulates hematopoietic stem cell (HSC) quiescence through phase separation-mediated inhibition of receptor signaling. The key objectives are to determine if DLK1 maintains and/or expands quiescent HSCs, elucidate how DLK1 interactions...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,209 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The goal of this 4-year project, starting May 1, 2025, is to develop and evaluate targeted nanoparticles for in vivo hematopoietic stem cell gene therapy to treat genetic blood diseases and disorders. Key objectives include optimizing nanoparticle formulations loaded with gene editing...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $160,518 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute. The 5-year grant, which began on August 15, 2024, supports the development of the principal investigator into an independent researcher in the field of immune modulation cell therapy for critically ill children, particularly those who have undergone...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,123,357 in funding to the Children's Hospital Medical Center in Cincinnati, Ohio for a research program focused on understanding the bone marrow microenvironment and its role in regulating blood cell production. The key goals of the 7-year research program are to: 1) Dissect the function of specialized microenvironments that serve as niches for different blood...